Compare Dyne Therapeutics Inc. Common Stock (DYN) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $59.36 (market cap $3.38B). The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is the larger of the two by market cap, and SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and SP Funds S&P 500 Sharia Industry Exclusions ETF for 66 Days on average.
| DYN | SPUS | |
|---|---|---|
Market Cap | $2.86B | $3.38B |
Volume | 3,341,579 | 308,295 |
Sector | Health | Broad Market / Factor |
52-Week High | $26.78 | $61.15 |
52-Week Low | $14.60 | $46.65 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
SPUS trades at $60.53, showing minimal daily movement with a slight decline of 0.07%. Technical indicators signal a bullish trend with strong moving average support, though oscillators remain neutral. The ETF maintains regular dividend distributions, with recent payments of $0.03 per share. Short interest saw significant growth in September, increasing 174.5% to 257,142 shares as of September 15, 2026.
The ETF's technical strength supports near-term upside potential, though elevated short interest indicates some bearish sentiment. Dividend consistency provides income appeal, but investors should monitor the growing short position which could increase volatility. The neutral oscillator readings suggest potential consolidation before further directional movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
